Spurned by AstraZeneca, is Pfizer out for GlaxoSmithKline?

Damian Garde The latest market chatter is that Pfizer, rebuffed in its quest to acquire AstraZeneca last year, is taking a hard look at GlaxoSmithKline, and one analyst says it might ...

Pfizer continues its deal spree with a $600M option pact to buy AM-Pharma

John Carroll Continuing a deal spree aimed at beefing up a weak pipeline, Pfizer has agreed to pay $ 87.5 million for a stake in the Dutch biotech AM-Pharma along with an option to ...

Pfizer settles lawsuits tying sex and gambling addictions to dopamine meds

Eric Palmer Pfizer is settling class-action litigation brought by patients who claimed the drugmaker did not adequately warn them of possible side effects of drugs they were taking ...

Mylan recalls injectable cancer meds, most produced for Pfizer

Tracy Staton Mylan is recalling 8 lots of injectable cancer drugs, most of them manufactured for Pfizer, after particulate was discovered in vials. FiercePharma News

Pfizer shutters vaccine sales business in China after Prevenar setback

Carly Helfand As it beefs up its vaccines business, Pfizer's looking to bolster revenue from the top-selling Prevenar family of shots. But on that front, it's come up against ...

Pfizer, Novartis: CDC’s MenB nod is too narrow

Carly Helfand Pfizer and Novartis have snagged a nod from the CDC's Advisory Committee on Immunization Practices (ACIP) for their recently approved meningitis B vaccines. ...

Exclusive: Pfizer is once again cutting back R&D staff in reorganization

John Carroll Pfizer is once again trimming its R&D staff. Responding to a query from FierceBiotech regarding word of cutbacks at research facilities in Cambridge, MA, and Collegeville, ...

Hospira CEO Ball stands to reap $80M on Pfizer buyout

Eric Palmer When Hospira's proxy was filed last year, CEO F. Michael Ball's $ 9.9 million in total compensation didn't even rank him among the top 15 highest paid biopharma ...

Pfizer grabs Hospira’s biosims, generic injectables in $15B takeover

Tracy Staton Pfizer has snapped up Hospira, an injectables specialist, for $ 90 per share, or some $ 15 billion, plus debt assumption. FiercePharma News

With Pfizer set to buy Hospira, what’s in the future for CEO F. Michael Ball?

Eric Palmer In four years as CEO of Hospira, F. Michael Ball has moved the company from its quality quagmire and a stock price collapse to an injectable drug leader and biosimilar player ...

Hospira may be just the tip of the iceberg for deal-hungry Pfizer

Carly Helfand Pfizer may have agreed on Thursday to pick up injectable drugmaker Hospira for $ 17 billion, but don't expect it to stop its dealmaking there, analysts say. FiercePharma ...

J&J, Pfizer, Novartis are the in-demand pharmas among job-seekers, LinkedIn says

Tracy Staton Hiring and keeping good employees is as much of a challenge in the drug business as it is anywhere else. So, it's always nice to know that would-be job seekers think ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS